Skip to main content
Premium Trial:

Request an Annual Quote

Tom Waddell

Tom Waddell has joined Xagenic as a vice president to lead the company's product development. Waddell was most recently with the assay research group at Abbott Point of Care where he managed a team that developed new product prototypes. He also worked with an Abbott group involved in regulatory approval processes. Before joining Abbott, Waddell was at Pro-Lab Diagnostics where he was involved in taking diagnostic tools from design to approval. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.